Sjögren’s Syndrome Treatments in the Microbiome Era

Abstract

Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by inflammatory cell infiltration of the salivary and lacrimal glands, resulting in acinar epithelial cell atrophy, cell death, and loss of exocrine function. At least half of SS patients develop extraglandular inflammatory disease and have a wide range of systemic clinical manifestations that can affect any organ system, including connective tissues. As many as 3.1 million people in the U.S. suffer from SS, a disease that causes severe impairment. Women are nine times more likely than men to be affected by this condition. Unfortunately, there is currently no effective treatment for SS, and the available options only provide partial relief. Treatment involves using replacement therapies such as artificial saliva and eye lubricants, or immunosuppressive agents that have limited efficacy. The medical community recognizes that there is a significant need for more effective treatments for SS. Increasing evidence demonstrates the links between the dysfunction of the human microbial community and the onset and development of many human diseases, signifying the potential use of microorganisms as an alternative strategy to conquer these issues. The role of the microbiome in controlling immune function of the human host in the context of autoimmune diseases like SS is now becoming better understood and may help to enable new drug development strategies. Natural probiotics and synthetic biology applications hold promise for novel treatment approaches to solve the encryption of many complex and multifactorial immune disorders, like SS.

Insights into Microbiota in Sjögren’s Syndrome

“…The link between the microbiota and tissue-dwelling dendritic cells, which is crucial for the development of immune memory and tolerance, should be emphasized. Recently, mechanisms regulating the reciprocal relationship between the microbiome and the adaptive immune system have been uncovered, in parallel to their influence on innate immune function [ 20 ]. The interface between gut microbiota and B cells promotes the proliferation of Forkhead box P3 (Foxp3+) regulatory T cells (Tregs).…”